Brain Trust Bio

Brain Trust Bio is a private, pre-revenue biotech company developing a precision intrathecal drug delivery platform to enhance existing CNS therapies. Founded in 2018 and based in San Francisco, the company has secured approval to initiate Phase I trials in Australia for its lead program, ITRil (intrathecal riluzole), for ALS, building on off-label treatment of two patients. The company's strategy centers on reformulating established drugs to achieve better efficacy and tolerability by delivering them directly to the cerebrospinal fluid, thereby accelerating development timelines and aiming for significant patient impact in debilitating neurological conditions.

Continuous intrathecal drug delivery platform designed to administer therapeutics directly into the cerebrospinal fluid to bypass systemic circulation, increase local CNS concentration, and reduce side effects.

Competition includes developers of novel ALS drugs (e.g., Amylyx, Biogen) and other drug delivery approaches. Brain Trust Bio's unique position is in reformulating an approved drug via a specialized delivery route, competing on enhanced efficacy/tolerability rather than novel mechanism, which is a less crowded but still challenging space.